Quoin Pharmaceuticals: 2026 AGM Results — Directors, 401(k) & NED Pay

What Happened

• Quoin Pharmaceuticals, Ltd. filed an 8‑K on August 20, 2026 reporting results from its 2026 Annual General Meeting held that day. Shareholders voted on five proposals including director elections, an advisory vote on executive pay, changes to non‑employee director (NED) compensation, amendments to 401(k) matching (including for U.S.‑based executives), and appointment of the independent auditor.
• On the record date of July 15, 2026 there were 70,294,615 ordinary shares outstanding (represented by 2,008,418 ADSs). All listed director nominees were elected; most received roughly 19.4 million "For" votes, though Natalie Leong received 16,807,490 "For" and 3,081,925 "Against."

Key Details

• Director elections (votes For/Against/Abstain; broker non‑votes shown): Dr. Michael Myers — 19,774,790 / 114,660 / 10,850 (BNV 16,285,325); Denise Carter — 19,432,490 / 456,715 / 10,885 (BNV 16,285,535); Joseph Cooper, James Culverwell, Dr. Dennis H. Langer, Michael Sember — ~19.4M For each; Natalie Leong — 16,807,490 For / 3,081,925 Against / 10,885 Abstain (BNV 16,285,325).
• Advisory vote on named executive officer compensation: approved (18,127,445 For; 556,430 Against; 1,216,425 Abstain; BNV 16,285,325).
• 401(k) matching changes (including for U.S.‑based executives): approved (19,245,870 For; 623,070 Against; 24,465 Abstain; BNV 16,292,220). The detailed summary of the 401(k) change is incorporated by reference from the Company’s Proxy Statement (filed July 16, 2026, see p.26).
• NED compensation amendments: approved (16,365,160 For; 3,517,080 Against; 18,060 Abstain; BNV 16,285,325). Amendments raise the annual base retainer up to $250,000 (set annually by the Compensation Committee/Board) and expand the annual option award value band to $20,000–$200,000.
• Auditor appointment: CBIZ CPAs P.C. was approved as the Company’s independent registered public accounting firm (votes: 35,488,320 For; 697,130 Against; 175 Abstain).

Why It Matters

• Governance: The re‑election of the board and the advisory approval of executive pay confirm shareholder support for current leadership and compensation policies. One director (Natalie Leong) drew notable opposition relative to others.
• Compensation & costs: Increasing the NED retainer (up to $250k) and larger option award ranges may raise director compensation expense going forward and could affect governance perceptions among investors.
• Employee pay & retention: Approved changes to 401(k) matching (including for U.S. executives) can affect employee benefits and may be used to attract/retain key staff.
• Audit oversight: Appointment of CBIZ CPAs P.C. as auditor is a material operational change for financial reporting and oversight.

For specifics on the 401(k) amendment text and full vote tables, see the Company’s definitive Proxy Statement (Schedule 14A filed July 16, 2026) referenced in the 8‑K.